88327-91-7

Basic information

• Product Name: 4-(PYRROLIDINE-1-SULFONYL)-PHENYLAMINE
• Synonyms: ART-CHEM-BB B000464;IFLAB-BB F1443-5503;AKOS BBS-00000293;AKOS BBB/017;AKOS B000464;4-(PYRROLIDINE-1-SULFONYL)-PHENYLAMINE;4-(PYRROLIDINE-1-SULFONYL)ANILINE;4-(PYRROLIDIN-1-YLSULFONYL)ANILINE
• CAS NO: 88327-91-7
• Molecular Formula: C₁₀H₁₄N₂O₂S
• Molecular Weight: 226.3
• Mol File: 88327-91-7.mol
• Article Data: 10

Chemical Properties

• Boiling Point: 407.8 °C at 760 mmHg
• Flash Point: 200.4 °C
• Appearance: /
• Density: 1.336 g/cm³
• Vapor Pressure: 7.36E-07mmHg at 25°C
• Refractive Index: 1.62
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 4-(PYRROLIDINE-1-SULFONYL)-PHENYLAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(PYRROLIDINE-1-SULFONYL)-PHENYLAMINE(88327-91-7)
• EPA Substance Registry System: 4-(PYRROLIDINE-1-SULFONYL)-PHENYLAMINE(88327-91-7)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38-36
• Safety Statements: 26-36/37/39
• HazardClass: IRRITANT
• Hazardous Substances Data: 88327-91-7(Hazardous Substances Data)

Usage

General Description

4-(Pyrrolidine-1-sulfonyl)-phenylamine is a chemical compound with a molecular formula of C10H14N2O2S. 4-(PYRROLIDINE-1-SULFONYL)-PHENYLAMINE contains a phenylamine component, which is an organic compound that is a subset of the class of anilines that consists of phenyl with an amino group. The pyrrolidine part of this compound is classified as a semisynthetic, antibacterial amino acid derivative. It is a protected form of L-pipecolic acid which is incorporated into peptide sequences. This chemical substance is used generally in the synthesis of other complex organic molecules. Its exact properties, functions, and potential uses in various fields are not widely reported, indicating that it may not be a common or well-studied compound.

InChI:InChI=1/C10H14N2O2S/c11-9-3-5-10(6-4-9)15(13,14)12-7-1-2-8-12/h3-6H,1-2,7-8,11H2

Upstream product

• 121-60-8 p-acetylaminobenzenesulfonyl chloride 
• 175278-37-2 1-((4-nitrophenyl)sulfonyl)pyrrolidine 
• 98-74-8 4-Nitrobenzenesulfonyl chloride 

Downstream Products

• 94243-29-5 [4-(Pyrrolidine-1-sulfonyl)-phenylamino]-acetonitrile 
• 88327-96-2 2-((4-(pyrrolidin-1-ylsulfonyl)phenyl)amino)acetic acid 
• 327067-60-7 C₁₇H₁₇FN₂O₃S 
• 349627-22-1 C₁₅H₁₆N₂O₄S 
• 327067-64-1 C₁₅H₁₆N₂O₃S₂ 
• 94243-35-3 C₁₂H₁₄N₄O₃S 
• 88328-02-3 C₁₂H₁₅N₃O₅S 

Relevant articles and documents

Optimization of norbornyl-based carbocyclic nucleoside analogs as cyclin-dependent kinase 2 inhibitors

We report on the discovery of norbornyl moiety as a novel structural motif for cyclin-dependent kinase 2 (CDK2) inhibitors which was identified by screening a carbocyclic nucleoside analogue library. Three micromolar hits were expanded by the use of medic

1,2-Benzisothiazol-3-one derivatives as a novel class of small-molecule caspase-3 inhibitors

A novel series of 1,2-benzisothiazol-3-one derivatives was synthesized and their biological activities were evaluated for inhibiting caspase-3 and -7 activities, in which some of them showed low nanomolar potency against caspase-3 in vitro and significant protection against apoptosis in a camptothecin-induced Jurkat T cells system. Among the tested compounds, compound 5i exhibited the most potent caspase-3 inhibitory activity (IC50 = 1.15 nM). The molecular docking predicted the interactions and binding modes of the synthesized inhibitor in the caspase-3 active site.

4,6-DIAMINONICOTINAMIDE COMPOUND

[Problem] The present invention provides a 4,6-diaminonicotinamide compound which is useful as an active ingredient of a pharmaceutical composition, in particular, a pharmaceutical composition for treating diseases caused by undesirable and/or abnormal cytokine signal transduction. [Means for Solution] The present inventors have extensively studied compounds having a JAK3 inhibitory action, and as a result, they have found that a 4,6-diaminonicotinamide compound which is the compound of the present invention has an excellent JAK3 inhibitory action and is useful as an agent for preventing or treating diseases caused by undesirable and/or abnormal cytokine signal transduction, thereby completing the present invention.